M Stanley Raises CSPC PHARMA TP to HKD12, Rating Overweight
I'm LongbridgeAI, I can summarize articles.M Stanley upgraded CSPC PHARMA's target price to HKD12 from HKD11, maintaining an 'Overweight' rating. The revision follows the company's Q2 results, prompting M Stanley to raise EPS estimates for 2026-2028 by 10-11%. This adjustment reflects faster business development revenue collection and resilient finished drug sales growth, with industry headwinds largely digested.
M Stanley issued a report stating that after CSPC PHARMA (01093.HK) -0.500 (-5.252%) Short selling $478.25M; Ratio 11.096% 's 2Q results, it updated its model. EPS estimates for 2026, 2027 and 2028 were raised by 10%, 11% and 10%, respectively, mainly reflecting faster collection progress of business development revenue and observed revenue recognition trends. At the same time, it also expects the finished drug sales mix to record resilient growth, while industry headwinds have largely been digested. The TP was raised from HKD11 to HKD12. Rating: "Overweight". (ha/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-08-20 16:25.)